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Available online 26 November 2016The QT interval on the human electrocardiogram is normally in the order of 450 ms, and reﬂects the summated
durations of action potential (AP) depolarization and repolarization of ventricular myocytes. Both prolongation
and shortening in the QT interval have been associatedwith ventricular tachy-arrhythmias, which predispose af-
fected individuals to sudden cardiac death. In this article, the molecular determinants of the AP duration and the
causes of long and short QT syndromes (LQTS and SQTS) are explored. This is followed by a review of the recent
advances on their arrhythmogenicmechanisms involving reentry and/or triggered activity based on experiments
conducted in mouse models. Established and novel clinical risk markers based on the QT interval for the predic-
tion of arrhythmic risk and cardiovascular mortality are presented here. It is concluded by a discussion on strat-
egies for the future rational design of anti-arrhythmic agents.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Wavelength1. Introduction
Long and short QT syndromes (LQTS and SQTS) are primary electri-
cal disorders of the heart that predispose the affected individuals to sud-
den cardiac death via the development of malignant ventricular
arrhythmias. Both syndromes can arise congenitally from ion channel
mutations, or can have acquired causes. In this article, the ionic basis
of the QT interval is examined, summarizing recent advances into the
electrophysiological mechanisms of arrhythmogenesis of both LQTS
and SQTS.
1.1. The QT interval
The QT interval of the human electrocardiogram (ECG) is a marker of
the duration of the cellular action potential (AP) [1]. It varies with heart
rate, and therefore a correction must be made before its interpretation.
Different formulae have been proposed for this purpose (Table 1). The
commonest is Bazett's formula, given by the QT interval divided by the
square root of the RR interval. However, this method overestimates QT
interval at high heart rates and underestimates it at low heart rates [2].
By contrast, Fridericia formula, in which QT interval is divided by the
cubic root of the RR interval, works better for slow heart rates. Other
methods include the Framingham and Hodges formulae. The upper
limit of a normal corrected QT (QTc) interval by Bazett's formula is
440 ms for males and 460 ms for females. The latest European Societyn@cuhk.edu.hk (B.P. Yan).
land Ltd. This is an open access articlof Cardiology guideline produced in 2015 suggests upper and lower
limits of 480 ms and 360 ms, respectively, for both males and females
[3]. The QT interval increases with age and long QT interval is commonly
associated with electrolyte abnormalities [4], drugs [5–7], medical
conditions such as epilepsy and diabetes mellitus [8,9]. The risk of
arrhythmogenesis is increased at both extremes of the QT interval. To
understanding why this is the case, the ionic determinants of the AP
and themechanisms bywhich their alterations lead to repolarization ab-
normalities must be considered.
1.2. Inward and outward currents determine the duration of the ventricular
APs
Generation of the ventricular APs is dependent upon voltage-gated
conductances, and AP durations are determined by the balance between
inward and outward currents. An AP has ﬁve phases: fast upstroke
(phase 0) followed by a spike (phase 1) and plateau (phase 2)morphol-
ogy, and further repolarization (phase 3), where the transmembrane
voltage returns to the resting membrane potential (phase 4) (Fig. 1).
Phase 0 is mediated by voltage-gated Na+ channels with rapid activa-
tion and inactivation kinetics. Phase 1 involves rapid repolarizationme-
diated by the fast and slow transient outward K+ currents, Ito,f and Ito,s,
respectively. Phase 3 is maintained by competing inward currents me-
diated by the voltage-gated L-type Ca2+ channel (ICa,L) and Na+-Ca2+
exchanger (INCX), and outward currents mediated by the voltage-
gated delayed rectiﬁer K+ channels (IK) [10]. Phase 3 can be explained
by a high driving force for K+ efﬂux due to a large potential difference
between the membrane potential and the K+ equilibrium potential.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Different methods of QT correction.
QT correction method Formula
Bazett QT/RR1/2
Fridericia QT/RR1/3
Framingham QT + 0.154 (1000 − RR)
Hodges QT + 105 (1/RR− 1)
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13], which is set by the inward rectiﬁer current, IK1 with contribution
from the weak inward rectifying ATP-dependent K+ channels (IK,ATP)
[14]. The QT interval includes the durations of both ventricular depolar-
ization and repolarization. Importantly, the end of repolarization (ac-
tion potential duration, APD) usually coincides with the resumption of
tissue excitability (effective refractory period, ERP).1.3. Long QT syndromes (LQTS)
Long QT syndromes (LQTS) is characterized by an abnormally long
QT interval of ≥450 ms on the ECG. The ﬁrst hereditary long QT syn-
drome was discovered by Jervell and Lange-Nielsen (JLN) in 1957 [15].
In this family, the parents had normal QT intervals and hearing, produc-
ing six children. Four suffered fromboth longQT interval and congenital
sensorineural deafness and the remaining two were normal. Three of
these four children suffered from sudden death. JLN syndrome was
later shown to have an autosomal recessive inheritance. In the 1960s,
Romano and Ward separately reported families suffering from QT pro-
longation but normal hearing, and the syndrome, after whom is
named, has an autosomal dominant inheritance [16].
LQTS is caused by a decrease in repolarizing currents or an increase
in depolarizing currents, with either congenital or acquired causes.
Today, thirteen genetic LQTS subtypes have been identiﬁed thus far.
Loss-of-functionmutations in the different types of K+ channels are re-
sponsible for LQTS types 1 (KCNQ1), 2 (KCNH2), 5 (KCNE1), 6 (KCNE2),
7 (KCNJ2) and 13 (KCNJ5). By contrast, gain-of-function mutations in
Na+ channel subunits lead to LQTS types 3 (SCN5A) and 10 (SCN4B),
and in the L-type Ca2+ channel produces LQT type 8 (CACNA1C, Timo-
thy syndrome). Mutations in supporting proteins are responsible for
the LQT type 4 (ANKB), 9 (CAV3), 11 (AKAP9) and 12 (SNTA1) pheno-
types. Recent studies have implicated calmodulin mutations in patients
suffering from a LQTS with previously unidentiﬁed genetic causes [17–
19]. Moreover, a long QT phenotype has been implicated in suddenFig. 1. Morphology of the human ventricular action potential. Phase 0 is the action
potential upstroke mediated by Na+ channel activation. Phase 1 represents early rapid
repolarization due to transient outward K+ currents. Phase 2 is the plateau phase
determined by a balance between inward Ca2+ and outward K+ currents. Phase 3 is late
repolarization attributed to delayed rectiﬁer K+ currents, bringing the membrane
potential back to the baseline (phase 4).unexpected death in epilepsy (SUDEP), caused by increased late Na+
current (INa, L) mediated by neuronal Na+ channel isoforms [20,21].
By contrast, acquired causes of LQTS aremuchmore common thange-
netic causes. These are commonly due to electrolyte abnormalities, most
frequently hypokalaemia. A hypokalaemia mouse model has been used
to study the arrhythmogenicmechanisms of LQTS, demonstrating several
consequences of APD prolongation (Table 2). Firstly, it increases the Ca2+
current available Na+ channel reactivation during the repolarizing phase,
leading to the development of early afterdepolarizations and subsequent
triggered activity (Fig. 2) [22]. Secondly, AP prolongation preferentially
occurs at the epicardium compared to the endocardium, resulting in an
increase in the transmural dispersion of repolarization (TDR) [22]. Re-
duced ERP of the ventricular myocardium [23] and unaltered conduction
velocity (CV) were observed, leading to a decrease in excitation wave-
length (λ) given by CV x ERP. λ is the path length that is occupied by
the action potential wave. Theoretically, a smaller λ canmore easily sup-
port a re-entrant circuit, thereby increasing the likelihood of reentrant ar-
rhythmias (Fig. 3). In congenital long QT syndromes, the ERP is not
typically altered. Similarly, CV is not reduced unless the speciﬁcmutation
produces loss-of-function mutations in Na+ channels, which may give
rise to overlapping phenotype of LQTS with Brugada syndrome and con-
duction defect [24–27]. Moreover, the emergence of APD alternans, at-
tributed to increased steepness of APD restitution together with the
abnormal repolarization gradient can lead to unidirectional conduction
block and thereby reentry [28,29].1.4. Short QT syndromes (SQTS)
Short QT syndrome (SQTS) is characterized by an abnormally short
QT interval of b350 ms on the ECG. It predisposes affected individuals
to an increased risk of atrial and ventricular arrhythmias, in particular
ventricular ﬁbrillation, and is therefore an important cause of sudden
cardiac death [30]. Shortening of QT interval reﬂects accelerated repolar-
ization, which can result from increased activity of repolarizing currents,
or decreased activity of depolarizing currents. SQTS, like LQTS, can have
congenital or acquired causes. Six genetic subtypes of SQTS have been
identiﬁed thus far. Gain-of-function mutations in the K+ channel
genes, KCNH2, KCNQ1 [31,32] and KCNJ2 [33] are responsible for SQT
types 1, 2 and 3, respectively. By contrast, loss-of-function mutations in
L-type Ca2+ channel subunits, CACNA1C, CACNB2 and CACNA2D1, are
found in SQT types 4, 5 and 6, respectively [34]. Interestingly, some pa-
tients diagnosed with Brugada syndrome have demonstrated shortened
QT intervals [34]. This is perhaps not surprising upon consideration of the
molecular mechanisms involved, because loss-of-function mutations in
the inward currents, which tips the net current in the outward direction,
are observed in both SQTS and Brugada syndrome. Acquired causes are
more common, including electrolyte abnormalities of hyperkalaemia or
hypercalcaemia, myocardial ischaemia, acidosis or carnitine deﬁciency
[35,36]. Hyperthermia can also cause a shortened QT interval, as can
drugs such as digitalis, acetylcholine, catecholamines or KATP activators.
Short QT intervals have also been associated with epilepsy, particularly
during the ictal and post-ictal states [8].
The mechanism of arrhythmogenesis in SQTS is less well-
understood than that of LQTS. Recent work in mice demonstrated
shortening in ERP in concert with APD [37], leading to decreased λ
and a higher risk of circus-type reentry. Abnormal APD restitution
leading to APD alternans is unlikely to play a role in SQTS because
only long diastolic intervals are engaged where the restitution
curve is ﬂat, unlike the case of LQTS where it was possible to engage
the steep portion of the restitution curve at low diastolic intervals
[28]. CV may be increased due to ERP shortening, but this would
not be expected to be pro-arrhythmic since this would increase rath-
er than decrease λ [38]. The similarities and differences of the elec-
trophysiological consequences of LQTS and SQTS are detailed in
Table 1.
Table 2
Electrophysiological changes observed in long and short QT syndromes (LQTS and SQTS). CV: conduction velocity. APD: action potential duration. ERP: effective refractory period. TDR:
transmural dispersion of repolarization. λ: excitation wavelength (CV × ERP).
Abnormalities LQTS SQTS References
Molecular mechanisms Increased inward currents or reduced outward currents Reduced inward currents or reduced outward currents [15,30]
Triggered activity Early afterdepolarizations from LTCC reactivation Not observed [86]
Substrates for reentry
CV ↔/↓ ↔/↑ [63]
APD ↑ ↓ [53]
ERP ↑ ↓ [63]
TDR ↑ ↑ [54,87]
λ ↓ ↓ [37,63]
APD alternans ↑ N/A [88,89]
CV restitution ↔ N/A [29,90,91]
APD restitution ↑gradient N/A [29,92,93]
VERP restitution ↑gradient N/A [94]
10 G. Tse et al. / IJC Heart & Vasculature 14 (2017) 8–131.5. Arrhythmic risk prediction: markers based on repolarization and QT
interval
Pre-clinical models have been useful for the studying the mecha-
nisms of cardiac arrhythmogenesis and provide a platform for testing
the arrhythmogenic potential of drugs [29,37,39–47]. Experiments in
these systems have demonstrated different arrhythmic risk markers,
such as increased TDR given by the maximum APD difference across
the myocardial wall [48], increased critical interval for re-excitation
given by the APD-ERP difference [23,49–51], shortened λ and reduced
λ-TRIAD (which is based on λ and repolarization properties of triangu-
lation, reverse use dependence, instability and dispersion: TRIaD) [52].
The clinical marker traditionally used for predicting arrhythmic risk
has been QTc [53]. However, its lack of accuracy led to the development
of othermarkers [52], such as QT dispersion (QTd) [54,55], interval from
the peak to the end of the T wave [56] (Tpeak – Tend, reﬂecting increased
TDR [57]), and (Tpeak – Tend)/QT ratio [58].
However, none of the above repolarization markers takes into ac-
count action potential conduction, yet λ, which incorporates both pro-
cesses, is an important determinant of arrhythmic risk [59–61]. Three
novel markers based on conduction-repolarization have been proposed
thus far. The ﬁrst is the index of Cardiac Electrophysiological Balance
(iCEB: QT/QRS) proposed by Lu and colleagues, which is a surrogate
marker of λ [62]. Indeed, this has demonstrated utility in predicting ar-
rhythmic risk in drug-induced settings, LQTS and Brugada syndrome
[63]. The other two markers, (Tpeak–Tend)/QRS and (Tpeak–Tend)/
(QT × QRS), have recently been put forward by Tse, but these remain
to be validated clinically. Tse's indices are based on the observations
that both conduction and repolarization abnormalities are important
in arrhythmogenesis and Tpeak–Tend was a signiﬁcant predictor of SCD
even after adjusting for, inter alia, QTc and QRS durations [64]. They
may therefore provide superior predictive values for arrhythmic riskFig. 2. Early afterdepolarizations can produce triggered activity, which can initiate
arrhythmias. Circus-type reentry requires slowed conduction, unidirectional conduction
block and a central obstacle around which the action potential wave can circulate.than the repolarization markers discussed above and even iCEB [65,
66]. Tse's indices were subsequently modiﬁed by Tse and Yan to incor-
porate QRS dispersion (QRSd) reﬂecting CV dispersion, yielding
QRSd × (Tpeak–Tend)/QRS, and QRSd × (Tpeak–Tend)/(QRS × QT) [67]. It
was proposed that the term QRSd/QRS could be a surrogate marker of
CV dispersion coefﬁcient based on the standard deviation of the mean
CV [68]. Other non-invasive methods of assessing the function of the
heart include magnetocardiography, which may provide additional in-
sights into risk stratiﬁcation in the future [69–76].
1.6. Therapeutic strategies
For LQTS, beta blockers are only effective in preventing ventricular
tachycardia in approximately 70% of the patients. The remaining 30%
are susceptible to arrhythmias. For SQTS, quinidine or disopyramide are
recommended. In both syndromes, deﬁnitive treatment is implantable
cardioverter-deﬁbrillator (ICD) insertion. There is therefore a need to de-
velop more effective agents for anti-arrhythmic therapy. A better under-
standing of the mechanisms of arrhythmogenesis would allow rational
drug design that aims to reverse the electrophysiological abnormalities
in question. Application of pre-clinical results to clinical medicine could
result in effective translation for the beneﬁt of patients, which is illustrat-
ed by the following two examples that demonstrate important proofs-of-
concept. Firstly, hypokalaemiamodelling LQTS produces AP prolongation,
reduced ERP, reduced λ, increased TDR, increased APD restitution slopes
and increased amplitude of APD alternans. Gap junction inhibition using
heptanol normalized ERP and therefore λwithout correcting for the re-
maining repolarization abnormalities [29]. Secondly, hyperkalaemia
modelling SQTS results in shortened APD and ERP, reduced λ and in-
creased TDR. Anti-arrhythmic effects of hypercalcaemia were associated
with reversal of ERP changes and normalization of λ, again without
correcting for the repolarization abnormalities [37]. Together, the above
studies demonstrate that prolonging myocardial refractoriness with an
aim of increasing λ is a viable strategy. Other approaches that have dem-
onstrated some success in pre-clinical models are increasing ERP or CV,
decreasing heterogeneities in CV, APD, ERP or Ca2+ transients, or sup-
pressing after depolarization phenomena (Fig. 4: modiﬁed from Tse et
al. with permission [28]). Novel agents using such strategies are gap junc-
tion inhibitors [77–80] and openers [81,82], stretch-activated channel
modulators, late sodium channel blockers [83], ryanodine receptor stabi-
lizers [84] and anti-ﬁbrotic agents [85]. It is likely that a systems physiol-
ogy approach will play a large role in studying the complex spatial and
temporal properties of cardiac dynamics. Its application will no doubt
transform arrhythmia management by identifying agents that have
lower toxicity and toxic side effects of currently available drugs.
Conﬂict of interest
None declared.
Fig. 3. Arrhythmogenic mechanisms in long and short QT syndromes. Prolongation in action potential duration (APD) can predispose to the development of early afterdepolarizations, in
turn producing triggered activity that can serve to initiate arrhythmias. Reentrant substrates may involve alterations in conduction velocity (CV), prolongation or shortening of APD or
shortening of effective refractory period (ERP). These abnormalities can in turn lead to increased transmural dispersion of repolarization (TDR), which can promote unidirectional
conduction block and an obstacle around which the action potential can circulate. Together with reduced wavelength (λ = CV × ERP), these can increase the susceptibility of
tachycardia by circus-type or spiral wave reentry.
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